
The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27 (local time). At the meeting, Professor Gustavo Werutsky of Moinhos de Vento Hospital in Porto Alegre, Brazil, presented patient-reported outcome (PRO) data from the phase III lidERA BC study (Abstract No. 538RO). The study evaluated the efficacy and safety of giredestrant, an oral selective estrogen receptor degrader (SERD), as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative (ER+/HER2−) early breast cancer. The PRO analysis showed that, alongside a significant improvement in invasive disease-free survival (iDFS), giredestrant effectively preserved patients' health-related quality of life (HRQoL) and daily functioning, while significantly reducing the burden of side effects and the risk of treatment discontinuation. Following his presentation, Oncology Frontier invited Professor Gustavo Werutsky for an interview to discuss the key findings and clinical implications of the lidERA BC PRO data, as well as their potential impact on the future landscape of adjuvant endocrine therapy.